Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:2742-53.

Slides:

Advertisements

Similar presentations

The EMERALD Trial Diabetic Substudy. EMERALD Diabetic Analysis To compare myocardial perfusion and infarct sizes in diabetic and non-diabetic patients.

Advertisements

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

Trial profile Fox K et al. Lancet 2008;372:

Trial Identification, Inclusion, and Exclusion Krista M. Dale et al, JAMA. 2006; 295:

Fructose & Diabetes Go to to download these slides for your presentations.

Journal Club Alcohol and Health: Current Evidence January–February 2007.

An Automated Internet Behavioral Weight-Loss Program by Physician Referral: A Randomized Controlled Trial Featured Article: J. Graham Thomas, Tricia M.

Individualizing Targets and Tactics for High- Risk Patients With Type 2 Diabetes Practical lessons from ACCORD and other cardiovascular trials Featured.

Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.

Effect of Lowering the Glycemic Load With Canola Oil on Glycemic Control and Cardiovascular Risk Factors: A Randomized Controlled Trial Featured Article:

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.

Relational Discord at Conclusion of Treatment Predicts Future Substance Use for Partnered Patients Wayne H. Denton, MD, PhD; Paul A. Nakonezny, PhD; Bryon.

Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Agility and Perturbation Training Techniques in Exercise Therapy for Reducing Pain and Improving Function in People With Knee Osteoarthritis: A Randomized.

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:

Trial profile Mann JF et al. Lancet 2008;372:

Extra-Virgin Olive Oil Reduces Glycemic Response to a High–Glycemic Index Meal in Patients With Type 1 Diabetes: A Randomized Controlled Trial Featured.

Siri, what should I eat? Zeevi et al. Personalized Nutrition by Prediction of Glycemic Responses. Cell 2015;163(5): Vanessa Ha.

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Date of download: 7/5/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of Dietary Composition on Energy Expenditure.

Early Neuromuscular Electrical Stimulation to Improve Quadriceps Muscle Strength After Total Knee Arthroplasty: A Randomized Controlled Trial by Jennifer.

Beaver Dam Eye Study: Overall Participant Flow Barbara E. K. Klein, et al. JAMA 2006;295:

Lacto-ovo vegetarian group

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

All-cause mortality by treatment group

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Nat. Rev. Neurol. doi: /nrneurol

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Trial profile John A Dormandy et al. Lancet 2005;366:

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Better Diabetes Control With Novel Basal Insulins

JAMA Pediatrics Journal Club Slides: Effect of Attendance of the Child in Childhood Obesity Treatment Boutelle KN, Rhee KE, Liang J, et al. Effect of attendance.

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

Daan Kromhout, et al. NEJM epub August 29, 2010

American Journal of Kidney Diseases

Enrollment and Outcomes

Population characteristics.

Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Flow of Patients Through the Trial

Changes In Nutrient Intake And Dietary Quality Among Participants With Type 2 Diabetes Following A Low-fat Vegan Diet Or A Conventional Diabetes Diet For.

Flow of Patients Through Trial

Study Participant Flow

Flow Diagram of the Trial Selection Process

Daily changes in ED use compared to baseline utilization in October and November 2012 for patients with diabetes in New York City evacuation zone level.

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Volume 368, Issue 9541, Pages (September 2006)

RECORD Study: Enrollment and Outcomes

PROSPER: trial design

(G) Body mass index (BMI) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (G) Body mass index (BMI) values.

Baseline characteristics of study population

Adjusted HRs (95% CIs) for all-cause mortality associated with BMI by smoking status in men and women and by CHD, type 2 diabetes, and cancer status at.

Adjusted HRs (95% CIs) for all-cause mortality associated with body fat percentage by smoking status in men and women and by CHD, type 2 diabetes, and.

Flow diagram illustrating diabetes outcomes in the randomly assigned treatment of folic acid and vitamins B6 and B12 of the WAFACS. A total of 1,190 participants.

Glycemic control and body weight over 52 weeks.

Changes (means±posterior SDs) in HbA1c (A), fasting glucose (B), and body weight (C) by treatment condition based on missing not at random (MNAR) analyses.

A1C at baseline and each maintenance month by treatment in the GEMINI trial, including the modified intention-to-treat population. A1C at baseline and.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

A1C at baseline, 16 weeks, and 32 weeks according to study group in all participants (A), adult participants (B), and adolescent participants (C) who returned.

Secondary outcomes: changes from baseline per treatment group (tolerance population). Secondary outcomes: changes from baseline per treatment group (tolerance.

Time course of daily basal and mealtime insulin dose (A), glycated hemoglobin (B), laboratory-measured clinic FPG (C), prebreakfast SMPG (D), SMPG profiles.

Presentation transcript:

Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:

Example Diets Based on 2000 Kilocalories a David J. A. Jenkin et al. JAMA 2008;300:

Baseline Characteristics of Study Participants David J. A. Jenkin et al. JAMA 2008;300:

Nutritional Profile of High–Cereal Fiber and Low–Glycemic Index Diets for Intention-to-Treat Population (n = 195) a David J. A. Jenkin et al. JAMA 2008;300:

Mean Study Measurements in Participants With Type 2 Diabetes Following Either a High–Cereal Fiber Diet or a Low–Glycemic Index Diet David J. A. Jenkin et al. JAMA 2008;300:

Mean Study Measurements and Significance of Treatment Differences for Intention-to-Treat Analyses (n = 210) David J. A. Jenkin et al. JAMA 2008;300:

Effect of Body Weight, Fiber, Glycemic Index, and Glycemic Load on Primary and Secondary Outcomes in the Intention-to-Treat Group David J. A. Jenkin et al. JAMA 2008;300:

Mean Study Measurements in Participants With Type 2 Diabetes Completing Either a High–Cereal Fiber Diet or a Low–Glycemic Index Diet David J. A. Jenkin et al. JAMA 2008;300: